Vaxcyte, Inc. $PCVX Shares Acquired by Boothbay Fund Management LLC

Boothbay Fund Management LLC lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 24.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 128,731 shares of the company’s stock after acquiring an additional 25,464 shares during the period. Boothbay Fund Management LLC owned approximately 0.10% of Vaxcyte worth $4,637,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Vaxcyte by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 12,320,453 shares of the company’s stock worth $443,783,000 after purchasing an additional 323,368 shares in the last quarter. Wellington Management Group LLP increased its stake in Vaxcyte by 1.6% during the 3rd quarter. Wellington Management Group LLP now owns 5,032,771 shares of the company’s stock valued at $181,280,000 after purchasing an additional 77,967 shares in the last quarter. State Street Corp raised its holdings in shares of Vaxcyte by 12.1% in the second quarter. State Street Corp now owns 4,942,235 shares of the company’s stock worth $160,672,000 after buying an additional 534,552 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Vaxcyte by 21.6% in the third quarter. Westfield Capital Management Co. LP now owns 3,732,715 shares of the company’s stock worth $134,452,000 after buying an additional 663,817 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Vaxcyte by 5.0% during the second quarter. Geode Capital Management LLC now owns 3,011,140 shares of the company’s stock worth $97,903,000 after buying an additional 142,086 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Price Performance

NASDAQ PCVX opened at $54.58 on Monday. The company has a market capitalization of $7.86 billion, a PE ratio of -9.71 and a beta of 1.31. The company has a fifty day moving average of $54.08 and a 200 day moving average of $46.01. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $76.61.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same period in the prior year, the business earned ($1.12) earnings per share. Research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 7,395 shares of Vaxcyte stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $58.88, for a total transaction of $435,417.60. Following the completion of the transaction, the chief operating officer directly owned 166,818 shares in the company, valued at approximately $9,822,243.84. This trade represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Elvia Cowan sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $58.59, for a total value of $146,475.00. Following the completion of the transaction, the chief accounting officer directly owned 30,867 shares of the company’s stock, valued at $1,808,497.53. The trade was a 7.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 31,261 shares of company stock worth $1,593,767 over the last quarter. 3.10% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PCVX shares. Needham & Company LLC boosted their price objective on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, January 9th. Guggenheim reiterated a “buy” rating and set a $116.00 price target on shares of Vaxcyte in a research note on Monday, February 2nd. BTIG Research increased their price objective on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Leerink Partners set a $77.00 price objective on Vaxcyte and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vaxcyte has an average rating of “Moderate Buy” and an average price target of $94.50.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.